Article

Pharmaceutical Company to Pay $95M to Settle Allegations of Improper Drug Promotion

Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday.

The Justice Department said the three are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent and the high-blood-pressure drug Micardis.

Read the full story: http://wapo.st/R32A1a

Source: The Washington Post

Related Videos
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Kimlin Tam Ashing
Jaime Almandoz, MD, MBA
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Leigh Maria Ramos-Platt, MD
Molly Dean, MSW, Siftwell
Molly Dean, MSW, Siftwell
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo